Journal
PHARMACOGENOMICS JOURNAL
Volume 14, Issue 3, Pages 223-228Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2013.34
Keywords
African Americans; algorithm; CYP2C9; polymorphisms; VKORC1; warfarin
Categories
Funding
- National Heart Lung and Blood Institute [K23 HL089808-01A2]
- American Heart Association Midwest Affiliate [10GRNT3750024]
- National Collaborative on Aging
Ask authors/readers for more resources
Using a derivation cohort (N=349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs). We tested our novel algorithm in an independent cohort of 129 AAs and compared the dose prediction to the International Warfarin Pharmacogenetics Consortium (IWPC) dosing algorithms. Our algorithm explains more of the phenotypic variation (R-2=0.27) than the IWPC pharmacogenomics (R-2=0.15) or clinical (R-2=0.16) algorithms. Among high-dose patients, our algorithm predicted a higher proportion of patients within 20% of stable warfarin dose (45% vs 29% and 2% in the IWPC pharmacogenomics and clinical algorithms, respectively). In contrast to our novel algorithm, a significant inverse correlation between predicted dose and percent West African ancestry was observed for the IWPC pharmacogenomics algorithm among patients requiring >= 60 mg per week (beta = -2.04, P=0.02).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available